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THE INTERESTING CASE 
Paraneoplastic Vitelliform Retinopathy Secondary to Metastatic Melanoma. 
 
Paolo Giovanni Meier, MD1 
Aude Ambresin MD1 
Charles E. Thirkill, MD, PhD2 
François-Xavier Borruat MD1 
Ann Schalenbourg, MD1  
 
1. Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital,  
FAA, Lausanne, Switzerland 
2. Eye Research Center, Davis Medical Center, University of California, Sacramento, 
US  
Correspondence to: 
Ann Schalenbourg, MD 
Adult Ocular Oncology 
Jules-Gonin Eye Hospital 
Avenue de France 15 
CH-1004 Lausanne 
Ph: +41-21-626-8111 
Fax: +41-21-626-8889 
Email: ann.schalenbourg@fa2.ch  
 
Financial interest: NONE 
Support: NONE 
BACKGROUND  
Traditionally, the paraneoplastic retinopathies have been classified into two entities: 
CAR (carcinoma-associated retinopathy) and MAR (melanoma-associated 
retinopathy). Recently, a vitelliform retinopathy has been described in both 
metastatic cancer and melanoma patients: in 2001, Borkowksy reported the first 
patient as a case of MAR with unusual retinal features [1]. Since then, only 20 cases 
have been reported [2-5]. This auto-immune disorder is caused by circulating 
autoantibodies, cross-reacting with the neuroretina and retinal pigment epithelium 
(RPE) [2]. 
 
HISTORY and SIGNS 
A 41-year-old lady, with pelvic lymph node metastases from an unknown melanoma 
was screened for her primary tumour. On ophthalmic examination, Snellen visual 
acuity (VA) was found to be 0.5 OU. She reported no blurred vision, nyctalopia or 
metamorphopsia. Ishihara colour vision and pupil light reflexes were normal. The 
anterior segment presented no signs of inflammation, and intraocular pressure was 
18 and 16 mmHg respectively in the RE and LE. Fundus examination revealed in 
both eyes multiple retinal detachments with a vitelliform sedimentation level, bullous 
in the macular area and subtle in the peripapillary regions (Figure 1 A-B). On Infrared 
Reflectance (IR), the number of retinal detachments appeared higher with the edges 
of the lesions clearly delineated (Figure 2, A-B). On blue light autofluorescence (AF), 
the pseudovitelliform deposits within the larger lesions showed a dense 
hyperautofluorescence (Figure 2, C-D). On fluorescein angiography (FA), the 
subretinal fluid provoked a slight masking effect in the LE in the early and late 
phases (Figure 2, E-F), while on indocyanine green angiography (ICG-A) a clear 
masking effect was caused by the lesions in all phases OU (Figure 2, G-H).  
Single line acquisition of SD-OCT across the fovea revealed OU a diffuse 
hyperreflective thickening of the external retina at the level of ellipsoidal zone and 
interdigitation layer, and a large subretinal fluid detachment with irregular 
hyperreflective deposits at the surface of the RPE layer. Subfoveal choroidal 
thickness of 417 μm (RE) and 427 μm (LE) was measured manually on an enhanced 
depth imaging (EDI) single line. Multifocal ERG recorded a reduction of amplitudes in 
the central 10-15° OU. The differential diagnoses included MAR, choroidal 
metastases, central serous chorioretinopathy, Best’s disease and paraneoplastic 
vitelliform retinopathy. A specific serum analysis was performed and revealed 
antibodies against a 45kDa retinal protein, probably the Pigment Epithelium-Derived 
Factor (PEDF).  
 
THERAPY and OUTCOME  
Patient underwent surgical excision of the inguinal metastatic lymph nodes. The 
postoperative evolution of both the visual function and fundus examination was 
stable. The indication of an immuno-regulatory treatment, such as steroids, 
plasmapheresis or monoclonal antibodies was considered. We decided for 
observation due the potential risk of an antagonistic effect against the patient’s own 
cancer antibodies with possibly deleterious consequences [6]. Six months later, VA 
had improved to 0.8 OU and on OCT both maculae were partially reapplied (Figure 
3, E-F).  
 DISCUSSION 
We present a rare case of pseudovitelliform retinopathy, extensively documented 
with multi-modal imaging and presenting antibodies against a 45KDa retinal protein 
probably the Pigment Epithelium-Derived Factor (PEDF). We speculate that a 
reduction in the tumour load might have played a significant role in the positive 
evolution of both visual function and retinal detachments. 
Multimodal imaging allowed us to narrow rapidly the differential diagnosis, as well as 
to precisely document periodic longitudinal evolution. Fundus examination revealed 
areas of retinal detachments, but a higher number of lesions were identified on IR 
and ICGA suggesting an important role in RPE dysfunction. Spaide et al. suggested 
that the thickening observed on SD-OCT in the external retinal layers is probably due 
to RPE dysfunction secondary to the important accumulation of hyperreflective 
pseudovitelliform material in the subretinal space [7].This partially explains the 
hyperreflectivity shown on OCT in our case when referring to the subretinal fluid 
accumulation. The thickened hyperreflective layer just adjacent to the inferior 
external retina suggests both an elongation of the outer segment of the 
photoreceptor and accumulation of inflammatory microglial cells possibly migrating 
from the neuroretinal tissue.  
Excessive production of cross-reacting antibodies against retinal structures has been 
found in most of the reported cases of PVR [1-4]. However, despite a similar retinal 
phenotype for the 20 reported cases, a variety of antibodies have been reported, 
suggesting specificity in the molecular mimicry of the primary tumour. Our case 
exhibited antibodies against a 45 KDa retinal antigen, possibly the Pigment 
Epithelium-Derived Factor (PEDF). There is no evidence based treatment for the 
management of CAR and MAR, the most frequent paraneoplastic disorders. 
Reduction of the tumour mass may have a beneficial effect on the ocular signs, due 
to a reduced level of autoantibodies synthesis [8]. Following tumour debulking 
surgery, the pseudovitelliform deposits and retinal detachments regressed, and VA 
improved to 0.8 OU. Unfortunately, the autoantibodies serum levels have not been 
measured since the metastases excision. However, the favourable clinical evolution 
seems to support the positive role of tumour load reduction as a first line treatment in 
such cases. To our knowledge, this is the first case of Paraneoplastic Vitelliform 
Retinopathy showing antibodies activity against a 45 kDa RPE protein.  
 
CONCLUSION 
Bilateral multiple vitelliform retinal detachments can be associated with metastatic 
disease. Serum retinal or RPE auto-antibodies support the diagnosis. Reducing the 
tumour load might stabilize this rare paraneoplastic retinopathy. 
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FIGURE LEGENDS: 
 
Figure 1. Bilateral Wide Field Fundus imaging at the initial visit (A-B) showing retinal 
detachments and pseudovitelliform deposits [RE is on the left, LE is on the right]. Six 
months later (C-D) the macular lesions were significantly less prominent.  
 
Figure 2.  
Bilateral baseline multimodal imaging at presentation (Heidelberg Engineering, 
Heidelberg, Germany). A-B. IR showing a higher number of retinal detachments as 
compared to the colour images. C-D. The pseudovitelliform deposits are 
hyperautofluorescent on AF. E-F. A slight masking effect on FA is present in the LE. 
G-H. Evident masking effect by all lesions on ICG-A. 
 
Figure 3. .  
OCT scans through macular region of the RE and LE at presentation (A-D) and after 
six months’ follow up (E-F) (Heidelberg Engineering, Heidelberg, Germany). A-D. 
Initial examination revealed subretinal fluid (arrowheads), thickening of the external 
layers (arrow) and an inhomogeneous pseudovitelliform sedimentation (asterisk). E-
F. The neuroretinal detachments have significantly regressed after tumour load 
reduction. 
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